changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination
This report describes a rare case of oligometastatic renal disease in a 69 year-old Caucasian male with non-small cell lung cancer (NSCLC). Diagnosed with Stage IIIb, NSCLC he completed chemoradiotherapy followed by 1 year of immunotherapy. Surveillance CT scans after nearly three years showed an il...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2023-06-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Subjects: | |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/3908 |
| _version_ | 1797782611823689728 |
|---|---|
| author | Elvis Matini Trishhani Yogaretnam Charlotte Alice Wilson Derek Power |
| author_facet | Elvis Matini Trishhani Yogaretnam Charlotte Alice Wilson Derek Power |
| author_sort | Elvis Matini |
| collection | DOAJ |
| description | This report describes a rare case of oligometastatic renal disease in a 69 year-old Caucasian male with non-small cell lung cancer (NSCLC). Diagnosed with Stage IIIb, NSCLC he completed chemoradiotherapy followed by 1 year of immunotherapy. Surveillance CT scans after nearly three years showed an ill-defined lesion in the left kidney.
Biopsy results were consistent with metastasis from the known lung carcinoma. Following neo-adjuvant Pembrolizumab (200mg, q3w), the patient underwent a left radical nephrectomy, without complications. One year post-operatively, CT of the thorax, abdomen and pelvis (TAP) did not identify any recurrence.
Renal metastases were historically demonstrated predominantly by autopsy studies[1]. Any mass manifesting in the kidney in the context of previous NSCLC warrants comprehensive investigations. The combination of immunotherapy followed by definitive treatment appears to be a promising management strategy[2]. With regards to local curative options, the advantages and disadvantages of surgery and radiotherapy have been well described[3-4]. |
| first_indexed | 2024-03-13T00:13:24Z |
| format | Article |
| id | doaj.art-475d141215cd4d2a9efe379327253bec |
| institution | Directory Open Access Journal |
| issn | 2284-2594 |
| language | English |
| last_indexed | 2024-03-13T00:13:24Z |
| publishDate | 2023-06-01 |
| publisher | SMC MEDIA SRL |
| record_format | Article |
| series | European Journal of Case Reports in Internal Medicine |
| spelling | doaj.art-475d141215cd4d2a9efe379327253bec2023-07-12T07:29:02ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942023-06-0110.12890/2023_0039083443changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combinationElvis Matini0Trishhani Yogaretnam1Charlotte Alice Wilson2Derek Power3Medical Oncology Department, Mercy University Hospital, Cork, T12 WE28, IrelandMedical Oncology Department, Mercy University Hospital, Cork, T12 WE28, IrelandMedical Oncology Department, Mercy University Hospital, Cork, T12 WE28, IrelandMedical Oncology Department, Mercy University Hospital, Cork, T12 WE28, IrelandThis report describes a rare case of oligometastatic renal disease in a 69 year-old Caucasian male with non-small cell lung cancer (NSCLC). Diagnosed with Stage IIIb, NSCLC he completed chemoradiotherapy followed by 1 year of immunotherapy. Surveillance CT scans after nearly three years showed an ill-defined lesion in the left kidney. Biopsy results were consistent with metastasis from the known lung carcinoma. Following neo-adjuvant Pembrolizumab (200mg, q3w), the patient underwent a left radical nephrectomy, without complications. One year post-operatively, CT of the thorax, abdomen and pelvis (TAP) did not identify any recurrence. Renal metastases were historically demonstrated predominantly by autopsy studies[1]. Any mass manifesting in the kidney in the context of previous NSCLC warrants comprehensive investigations. The combination of immunotherapy followed by definitive treatment appears to be a promising management strategy[2]. With regards to local curative options, the advantages and disadvantages of surgery and radiotherapy have been well described[3-4].https://www.ejcrim.com/index.php/EJCRIM/article/view/3908oligometastatic renal diseaseimmunotherapysquamous nsclcnephrectomy |
| spellingShingle | Elvis Matini Trishhani Yogaretnam Charlotte Alice Wilson Derek Power changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination European Journal of Case Reports in Internal Medicine oligometastatic renal disease immunotherapy squamous nsclc nephrectomy |
| title | changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination |
| title_full | changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination |
| title_fullStr | changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination |
| title_full_unstemmed | changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination |
| title_short | changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination |
| title_sort | changing face of lung cancer oligometastatic renal metastasis post chemo immunotherapy combination |
| topic | oligometastatic renal disease immunotherapy squamous nsclc nephrectomy |
| url | https://www.ejcrim.com/index.php/EJCRIM/article/view/3908 |
| work_keys_str_mv | AT elvismatini changingfaceoflungcanceroligometastaticrenalmetastasispostchemoimmunotherapycombination AT trishhaniyogaretnam changingfaceoflungcanceroligometastaticrenalmetastasispostchemoimmunotherapycombination AT charlottealicewilson changingfaceoflungcanceroligometastaticrenalmetastasispostchemoimmunotherapycombination AT derekpower changingfaceoflungcanceroligometastaticrenalmetastasispostchemoimmunotherapycombination |